Patent ID: 11951167
Assignee: GEORGETOWN UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 15:
16. A method of treating a brain cancer in a patient, comprising:
(a) preparing a targeted temozolomide cationic liposome complex, comprising
i. preparing a lipid solution comprising 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in ethanol;
ii. preparing a solution of temozolomide;
iii. mixing the lipid solution with the solution of temozolomide;
iv. injecting the mixture of lipid and temozolomide into an aqueous solution, thereby forming a temozolomide cationic liposome;
v. mixing the temozolomide cationic liposome with an anti-transferrin receptor single chain Fv (TfRscFv) to form the targeted temozolomide cationic liposome complex, wherein the TfRscFv is directly complexed with, but not chemically conjugated to, the cationic liposome;

(b) administering via intravenous administration to the patient the targeted temozolomide cationic liposome complex;
(c) delivering the targeted temozolomide cationic liposome complex across the blood-brain barrier of the patient;
(d) delivering the temozolomide to the brain cancer; and
(e) inducing growth inhibition and/or regression of the brain cancer.